19th Apr 2023 15:40
ImmuPharma PLC - London-based drug discovery and development company - Notes the US Food & Drug Administration has set a date of June 7 for a type-C meeting to provide guidance on the phase 2/3 adaptive study of Lupuzor, or P140, in patients with systemic lupus erythematosus, a common type of immune disease lupus. Says this follows the announcement in late March, when it submitted a phase 2/3 clinical trial protocol to the US FDA testing the Lupuzor treatment for lupus patients.
Chief Executive Officer Tim McCarthy says: "Following on from our announcement last week of the pre-IND meeting with the FDA [...] we are delighted to confirm this meeting date with the FDA on P140 in lupus. With the prospect of both of these indications moving positively forward into pivotal studies in H2 2023 there is real value momentum building in our P140 franchise."
Current stock price: 3.03 pence, up 2.7%
12-month change: down 57%
By Greg Rosenvinge, Alliance News reporter
Comments and questions to [email protected]
Copyright 2023 Alliance News Ltd. All Rights Reserved.
Related Shares:
Immupharma